key: cord-0429406-4e82692b
authors: Ouahed, J. D.; Broggi, A.; Glick, A.; Haring, R. T.; Michael, F.; Chinnapen, D.; Grey, M. J.; Lencer, W. I. J.; Steiner, S. J.; Dennis-Hyeward, E.; Shroyer, N. F.; Chriss, Z.; Lin, S.-C.; Zeng, X.-L.; Crawford, S.-E.; Estes, M. K. F.; Thiagarajah, J. R.; Capilla, A.; Scoon, W.; Mostoslavsky, G.; Spence, J. R.; Klein, C.; Muise, A.; Horwitz, B.; Zanoni, I.; Snapper, S. B.
title: Variants in Interferon Lambda are Associated with Infantile-Onset Inflammatory Bowel Disease
date: 2022-03-20
journal: nan
DOI: 10.1101/2022.03.17.22271929
sha: 6a11eec499dfc0e42e7d532fc71662d8e1dc41c4
doc_id: 429406
cord_uid: 4e82692b

Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the intestine that affect children and adults. The etiology is multifactorial with the contribution of genetic, immune, microbial, and environmental risk factors with a substantial involvement of host:microbial cross-talk in the lumen. Whether and how antiviral responses contribute to IBD pathogenesis is under intense investigation. Here, we identified two unrelated patients diagnosed with infantile-onset IBD with rare variants in type III Interferons (IFNs), also known as interferon lambdas, a group of IFNs that play key roles in the protection against enteric viruses. The first patient was found to have homozygous variants in both IFNL2 and IFNL3, the genes encoding, IFN lambda-2 and IFN lambda-3, respectively. The second patient was found to have inherited compound heterozygous variants in IFNL3, with one of the two alleles bearing the same variant as the first patient. Functional analyses revealed that the proteins coded for by these variant IFN-lambda genes exhibited defects in the induction of IFN signaling. More detailed assessment of the variants identified in Patient 1 demonstrated defects in their ability to bind to IFN lambda receptor 1 (IFNLR1), as well as their ability to induce heterodimerization of IFNLR1 and IL10RB, which together compromise the functional receptor for IFN lambda (IFNLR). These patient-encoded IFN lambda variants also exhibit defects in the ability to induce robust downstream IFN-stimulated genes (ISGs) in patient-derived intestinal organoids. All in all, we demonstrate that infantile-onset IBD is associated with variants in IFN lambdas and defective induction of downstream IFN signaling.

Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the intestine that affect children and adults. The etiology is multifactorial with the contribution of genetic, immune, microbial, and environmental risk factors with a substantial involvement of host:microbial crosstalk in the lumen. Whether and how antiviral responses contribute to IBD pathogenesis is under intense investigation. Here, we identified two unrelated patients diagnosed with very early onset IBD (VEOIBD) with rare variants in type III Interferons (IFNs), also known as interferon lambdas (IFNλs), a group of IFNs that play key roles in the protection against enteric viruses. The first patient was found to have homozygous variants in both IFNL2 and IFNL3, the genes encoding, IFN-λ2 and IFN-λ3, respectively. The second patient was found to have inherited compound heterozygous variants in IFNL3, with one of the two alleles bearing the same variant as the first patient. Functional analyses revealed that the proteins coded for by these variant IFN-λ genes exhibited defects in the induction of IFN signaling. More detailed assessment of the variants identified in Patient 1 demonstrated defects in their ability to bind to IFN-λ receptor 1 (IFNLR1), as well as their ability to induce heterodimerization of IFNLR1 and IL10RB, which together compromise the functional receptor for IFN-λ (IFNLR). These patient-encoded IFN-λ variants also exhibit defects in the ability to induce robust downstream IFN-stimulated genes (ISGs) in patientderived intestinal organoids. All in all, we demonstrate that VEOIBD is associated with variants in IFN-λs and defective induction of downstream IFN signaling.

Inflammatory bowel diseases (IBDs), encompassing Crohn's disease and ulcerative colitis, are chronic inflammatory conditions affecting the intestines. IBD is now considered a global disease, with prevalence exceeding 0.3% in North America 1 . While most patients are diagnosed in adulthood, IBD also affects infants and young children. Diagnosis before 6 years of age, referred to as very early onset IBD (VEOIBD) 2 , represents the group with the fastest rising incidence of IBD 3 . Overall, the etiology of IBD is felt to be multifactorial with contributions of genetic, immune, microbial, and environmental risk factors.

Large adult-based Genome Wide Association Studies (GWAS) have identified nearly 250 loci that confer significant risk for IBD susceptibility [4] [5] [6] . It has been hypothesized that the genetic contribution of VEOIBD is larger than that in patients diagnosed at older ages; currently over 75 monogenic causes of VEOIBD have been identified with many reflecting underlying primary immune deficiencies [7] [8] [9] [10] [11] . These advances have not only significantly expanded our understanding of the pathophysiology of IBD but importantly, they also enable personalized and often curative interventions.

Crosstalk between the microbiome and the genetically susceptible host 12-18 is a central factor in the development of IBD. However, recent data has also implicated the virome in mucosal homeostasis [19] [20] [21] [22] [23] [24] [25] , and interestingly, to date, none of the currently identified monogenic causes of VEOIBD directly implicate defects in viral recognition or clearance. Interferons (IFNs) are most known for their inherent anti-viral activities and protect against enteric viral infections [26] [27] [28] [29] [30] [31] [32] [33] [34] . IFNs are divided into three classes: type I IFNs (including IFN-α and IFN-β), type II IFN (IFN-γ) and the more recently identified type III IFNs or IFN-λs (including IFN-λ1-4 in humans [35] [36] [37] ). Murine models have suggested potential anti-inflammatory functions for type I IFNs within the intestine 38 , and based on this, type I IFNs were assessed for therapeutic efficacy in IBD 39, 40 . However, these trials failed to demonstrate therapeutic efficacy; in fact type I IFNs exacerbated intestinal inflammation in some cases 41 . Recent murine studies revealed potential insight into these failures including opposing effects of type I IFN signaling on individual cell types 42 . Also, type I IFN-dependent ISGylation of proteins produces reactive oxygen species and augments colonic inflammation 43 .

IFN-λs were initially believed to have functions redundant with those of type I IFNs. However, more recent research by our group has established unique characteristics of IFN-λs. IFN-λs can induce signaling in both murine and human neutrophils 44 . IFN-λ suppresses the tissue damaging functions of neutrophils and the specific loss of IFN-λ signaling in neutrophils exacerbates DSSinduced colitis in mice 44 . This may have important therapeutic implications as the exogenous administration of IFN-λ reduces intestinal inflammation, whereas IFN-λ blockade enhances intestinal inflammation 44 . Also, it has recently been shown in mice that IFN-λ participates in the generation of amphiregulin for regeneration of intestinal epithelium 45 . While previous studies have demonstrated that expression of IFN-λ and its receptor, the interferon lambda receptor (IFNLR), are upregulated within the colon of patients with IBD, the effects of IFN-λ signaling during IBD development are incompletely understood 46, 47 . Nonetheless, IFN-λ demonstrates features which support a potential role in protection against intestinal inflammation [48] [49] [50] [51] . First, IFN-λ belongs to the IL-10 cytokine family and IFN-λs are structurally more similar to the anti-inflammatory cytokine IL-10 than type I IFNs. The IFNLR comprises a heterodimer consisting of IL10RB (shared by IL-10, IL-22 and other cytokines) and IFNLR1, which confers IFN-λ recognition. Pertaining specifically to impaired mucosal homeostasis, the absence of IL10RB signaling in innate immune cells results in life-threatening VEOIBD, with a major role for IL-10 signaling residing in phagocytes 52 . Secondly, IFN-λs activate only a subset of the genes that are activated by type I IFNs, with the different signaling capacities of the two IFN groups explained, at least in part, by their activation of different JAK-STAT members 44, 49, 53 that have been found to be associated to IBD through GWAS studies [54] [55] [56] . Finally, the cellular targets of IFN-λs are much more limited and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2022 defined, compared to those of type I IFNs, because the IFNLR1 is almost exclusively expressed on epithelial cells and neutrophils, suggesting tissue-specific functionality 48, 57 .

Here, we describe two patients from two unrelated families that have rare variants in IFN-λ in association with VEOIBD. Functional studies demonstrate that the variants lead to defects in binding to the heterodimeric IFNLR and induction of IFN signaling.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2022 

The first patient, P1, presented with bloody diarrhea in the first months of life. He was formally diagnosed with indeterminate colitis at 1 year of age following endoscopic ( Figure 1A ) and histologic findings consistent with VEOIBD. He also experienced large joint arthritis and intermittent fevers. His disease was well managed on the immune modulator 6-mercaptopurine.

The medication was discontinued by 5 years of age but symptoms recurred several years later.

Reinitiation of 6-mercaptopurine with adequate levels failed to control disease.

The second patient, P2, presented with bloody stools also in the first months of life. By 1 year of age he was found to have endoscopic ( Figure 1A ) features consistent with VEOIBD. Parents refused medical therapeutic intervention. By 5 years of age, parents report that his condition spontaneously improved with complete resolution of his bloody stools.

To identify potential monogenic causes of VEOIBD, whole genome sequencing (WGS) was performed on P1 and his healthy parents. No rare variants in genes known to be responsible for VEOIBD were identified. Whole exome sequencing (WES) was performed on P2 and his healthy parents and similarly did not reveal rare variants in genes associated with VEOIBD.

To identify potential novel monogenic causes of P1 and P2's VEOIBD, we evaluated the presence of rare variants in genes not currently known to be related to VEOIBD. In P1, we identified homozygous missense mutations in both IFN-λ2 and IFN-λ3, which are arranged in a cluster of IFN-λ genes on chromosome 19. The mutation in IFN-λ2 is c.461G>A; p.Arg154His, referred to as "IFN-λ2Var" for the remainder of this manuscript. The mutation in IFN-λ3 is c.383A>G;

p.His128Arg, referred to as "IFN-λ3Var1" for the remainder of this manuscript (Figure 1B and   1C ). The IFN-λ2Var had a minor allele frequency (MAF) of <0.1% in both 1000 Genomes Project 58 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In P2, we identified biallelic rare missense variants in IFN-λ3 ( Figure 1B and 1C) ; specifically, c.383A>G; His128Arg (i.e., IFN-λ3Var1 identified in P1), as well as c.511G>A; p.Glu171Lys, referred to as "IFN-λ3Var2" for the remainder of this manuscript. The latter missense mutation had a minor allele frequency < 0.1% and was reported 9 times in a homozygous recessive fashion in ExAC. These mutations were confirmed by Sanger sequencing (not shown) and found to be present in a compound heterozygous fashion in the patient as illustrated in the pedigree in Figure   1B .

Mapping of the mutation on a published crystal structure of IFN-λ3 complexed with the heterodimeric receptor, consisting of IFNLR1 and IL10RB, 60 revealed that IFN-λ3Var1 was situated in a site close to the residues critical for IL10RB binding ( Figure 1D, right panel) . IFN-λ3Var2 is located closer to the binding site of IFNLR1 ( Figure 1D, right panel) . Given the great similarity between IFN-λ3 and IFN-λ2 (which share 96% amino acidic sequence identity) 61 , we mapped the location of IFN-λ2Var on the IFN-λ3-IL10RB-IFNLR1 crystal complex. IFN-λ2Var appeared situated near the binding site of IFNLR1 ( Figure 1D , left panel).

We sought to determine whether the rare patient-encoded variants in IFN-λ2/3 resulted in defective downstream signaling. Upon binding of IFN-λ to the IFNLR, activation of JAK1 and JAK2 or TYK2 results in phosphorylation of STAT1, STAT2 and recruitment of IRF9, and formation of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2022. ;  the ISGF3 complex. ISGF3 binds IFN sensitive response elements (ISREs) and induces a variety of downstream IFN-stimulated genes (ISGs) which confer antiviral activity. To determine the capacity of the patient-encoded variants to induce signaling downstream of the IFNLR, we employed a luciferase reporter assay driven by the ISRE promoter and assessed relative luciferase activity as a proxy for induction of downstream ISGs in 293T cells 49 

We have shown that both P1 and P2 harbor variants in IFN-λ2 and IFN-λ3 that display defective signaling in a reporter cell line. To assess whether these defects are conserved in patient-derived intestinal epithelial cells, we focused on PI and differentiated, as previously described 62 , human intestinal organoids (HIOs) from induced pluripotent stem cells (iPSCs) derived from his PBMCs as well as from his parents. These in vitro HIOs were then transplanted in immunodeficient mice, subsequently the epithelium of the transplanted HIOs (tHIOs) were extracted and expanded to facilitate further study. As controls, we also evaluated human intestinal enteroids derived from duodenal biopsies (SI) or colon biopsies (CO) of healthy controls. We then determined whether P1 or P1 parent tHIOs responded to WT or mutant IFN-λs by measuring by qPCR the induction of a set of 3 ISGs, whose mean expression was quantitated as an "ISG score" as previously described 63 . Our data not only confirmed that IFN-λ2 and IFN-λ3 variants are hypoactive ( Figure   2E , Supp Figure 1F ), but also demonstrated that P1 tHIOs responded normally to WT IFN-λ3 ( Figure 2E ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2022. ;

To interrogate the basis for the deficient downstream signaling of patient-encoded variants, we sought to determine in P1 whether the IFN-λ2 and IFN-λ3 variants resulted in either altered receptor binding and/or impaired dimerization of the heterodimeric IFN-λ receptor. As IFN-λ directly binds IFNLR1, and does not bind directly to the IL10RB component of the heterodimeric receptor 60 , we focused our attention on the capacity of WT IFN-λs and variant IFN-λs to bind IFNLR1.

We employed a bio-layer interferometry (BLI)-based receptor binding affinity assay to assess binding of WT IFN-λ2 and P1-encoded IFN-λ2Var to IFNLR1. Reduced binding affinity was detected in the patient-encoded protein (KD 2.5x10 -6 M, versus 2.0x10 -7 M) ( Figure 3A) . The receptor binding affinity assay was also performed with WT IFN-λ3 and the shared patientencoded IFN-λ3Var1. Compared to WT IFN-λ3, IFN-λ3Var1 had reduced binding affinity to IFNLR1 (KD 1.0x10 -6 M, versus 5.9x10 -8 M) ( Figure 3B ).

Similar to other IL-10 family cytokines, IFN-λs are recognized first by the specific subunit of their dimeric receptor, i.e., IFNLR1. Upon binding to IFNLR1, they recruit and bind to IL10RB. Receptor dimerization is thus the first step to induce signaling. As described above, IFN-λ3Var1 and IFN-λ2Var had reduced binding affinity to IFNLR1. We then sought to assess whether P1-associated variants resulted in impaired dimerization of the IFNLR heterodimeric receptor. We used an IFNLR1/IL10RB dimerization assay (PathHunter eXpress, Europhins DiscoverX Products) in which each component of the heterodimeric receptor is linked to a portion of an enzyme with bgalactosidase activity. Namely IFNLR1 is linked to an enzyme acceptor (EA) and IL10RB is linked to a ProLink (PK) enzyme. Each component individually lacks b-galactosidase activity ( Figure   . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2022. ; https://doi.org/10.1101/2022.03.17.22271929 doi: medRxiv preprint

While an abundance of genetic and functional studies has supported dysregulation of intestinal bacteria in association with IBD, there has been enhanced focus on the contribution of other microbes, and notably viruses, in disease pathogenesis [19] [20] [21] [22] [23] [24] [25] . IBD risk polymorphisms have been described (e.g., FUT2 and FUT3) that may regulate the replication of enteric viruses 25, 64 .

Nonetheless, to our knowledge, no monogenic cause of IBD associated with a specific defect in enteric virus infection has been reported to date.

Here we present two unrelated patients with VEOIBD who inherited rare recessive missense In particular, while ISGs that are induced by type III IFNs are expressed in subsets of mature enterocytes in the small intestine at homeostasis 69 , a comprehensive understanding of the specific cellular, developmental (e.g., peri-natal versus post-natal), and geographic (e.g., small versus large intestine) landscape of type III IFN expression in the human intestine is lacking.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2022. ; https://doi.org/10.1101/2022.03.17.22271929 doi: medRxiv preprint While we have identified rare IFN-λ variants that are functionally deficient in our described patients, it remains to be determined definitively whether these functional deficits relate directly to impaired mucosal homeostasis and development of VEOIBD. These possibilities are not mutually exclusive and require further investigation needs to be pursued.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2022. ; https://doi.org/10.1101/2022.03.17.22271929 doi: medRxiv preprint

Patients were referred to us at Boston Children's Hospital from offsite centers through the very early onset IBD consortium (www.veoibd.org). Patients and parents included in this study provided informed consent and assent where applicable. Consent was obtained as per our Whole genome sequencing was performed as described 74 using the HiSeq platform (Illumina) with the Burrows-Wheeler aligner, and Picard was used for basic alignment and sequence quality control. The same capture kits and strategies were employed for the genome sequencing as described above for whole exome sequencing.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Samples were analyzed by gel filtration chromatography for monodispersity and differential scanning fluorimetry for thermal stability.

293T cells expressing Luciferase under the control of an ISRE promoter 49 were plated at a concentration of 400,000 cells/ml of 293T medium (RPMI medium 1640 1X 500 ml, 1% glutamax, 10% filtered fetal bovine serum (FBS), 1% Pen-strep, 1% non-essential amino acids, 1% sodium pyruvate (ThermoFisher Scientific)) using 100ul per well on a 96-well flat bottom plate in the morning. After adhering to the well, the cells were stimulated with different concentrations of either WT purified protein or patient-encoded proteins. Following overnight stimulation at 37°C, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2022. ;  luciferase activity was quantified the following morning using Bright-Glo luciferase assay system (Promega, Madison, WI) on a Tecan plate reader (Männedorf, Switzerland). For assessment of IFN-λ2 and IFN-λ2Var, experiments were performed in triplicates, at concentrations between 0-1800 ng/ml. For assessment of IFN-λ3, IFN-λ3Var1 and IFN-λVar2, experiments were performed > 3 times, with consistent results at concentrations between 0-200 ng/ml.

Binding of IFN-λ3, IFN-λ2 and patient derived variants to IFNLR1 was evaluated via biolayer interferometry (BLI) using an Octet RED384 (Fortebio). With BLI, one molecule is immobilized to a Dip and Read Biosensor and binding to a second molecule is measured as a shift in the light interference pattern measured in real time. We first loaded an anti-human IgG Fc Capture (AHC) Biosensor (Fortebio) with 10 μg/ml of recombinant IFNLR1-Fc chimeric protein (R&D Systems) for 120 sec in the presence of assay buffer (PBS 0,5% Tween-20). The biosensor was then transferred to a different well containing IFN-λ2, IFN-λ3 or patient-derived variants. A range of concentration was assessed (2μM -1μM -0.5μM -0.125 μM -0.0625 μM) and association to IFNLR1 was measured over 300s. Following the association step, the biosensor was transferred in a well containing assay buffer alone and dissociation was measured over 600s. Association curves were normalized based on the signal of the last 2 seconds of the loading step. Dissociation constants (KD) were calculated using the Octet Data Analysis HT Software.

As per the protocol for PathHunter eXpress IFNLR1/IL10RB dimerization Assay protocol (Eurofins DiscoverX Products, San Francisco, CA), cells provided in the kit were thawed as per protocol.

Increasing concentrations of IFN-λ2 and IFNλ-3 and patient-encoded variants were added to a final concentration of 0 to 500ng/ml. Cells were stimulated for 6 hours at 37°C prior to adding . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2022. ;  https://doi.org/10.1101/2022.03.17.22271929 doi: medRxiv preprint 110ul of PathHunter Flash Detection reagents to each well, as per protocol. Cells were then incubated at room temperature in the dark for 1hr and luciferase was read using a Tecan plate reader (Männedorf, Switzerland).

Induced Pluripotent Stem Cells (iPSCs) were derived from patients' and healthy parents' Peripheral Blood Mononuclear Cells (PBMCs) as previously described 75 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2022. ;  described. Briefly, enteroids were passaged by removal of Matrigel with Cell Recovery Solution (Corning) for 30 min at 4°C. After incubation organoids were mechanically dissociated and replated in Matrigel every 4 days.

To compare two groups unpaired t-test were performed. When data did not meet the normality assumption, significance was assessed by Mann-Whitney test. To establish the appropriate test, normal distribution and variance similarity were assessed with the D'Agostino-Pearson omnibus normality test. Dose response curves were fitted with a Richard's five parameters dose response curve. EC50 and area under the curve (AUC) were calculated with GraphPad PRISM software.

All statistical analyses were two-sided and performed using GraphPad PRISM software software and are indicated in figure legends. Throughout the paper significant is defined as follows: ns, not significant (p > 0.05); *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

The age of gene discovery in very early onset inflammatory bowel disease

Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease

Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations

Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease

Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms

Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies

Exome sequencing analysis reveals variants in primary immunodeficiency genes in patients with very early onset inflammatory bowel disease

The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel Disease

Clinical Genomics for the Diagnosis of Monogenic Forms of Inflammatory Bowel Disease: A Position Paper From the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition

Role of the gut microbiota in immunity and inflammatory disease

The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models

Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases

Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis

Diet-microbiota interactions as moderators of human metabolism

Gut microbiota, metabolites and host immunity

Gut microbiota-generated metabolites in animal health and disease

Enteric Viruses Ameliorate Gut Inflammation via Toll-like Receptor 3 and Toll-like Receptor 7-Mediated Interferon-beta Production

Disease-specific alterations in the enteric virome in inflammatory bowel disease

Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine

Dynamics of the Stool Virome in Very Early-Onset Inflammatory Bowel Disease

Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria

Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches

Enteric Viruses and Inflammatory Bowel Disease

Commensal microbes and interferon-lambda determine persistence of enteric murine norovirus infection

IFN-lambda determines the intestinal epithelial antiviral host defense

Leukocytederived IFN-alpha/beta and epithelial IFN-lambda constitute a compartmentalized mucosal defense system that restricts enteric virus infections

Distinct Roles of Type I and Type III Interferons in Intestinal Immunity to Homologous and Heterologous Rotavirus Infections

Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection

Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity

Interferon-stimulated genes: a complex web of host defenses

Homeostatic interferon-lambda response to bacterial microbiota stimulates preemptive antiviral defense within discrete pockets of intestinal epithelium

Microbiota regulation of viral infections through interferon signaling

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

IL-28, IL-29 and their class II cytokine receptor IL-28R

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

Toll-like receptor 9-induced type I IFN protects mice from experimental colitis

Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study

Clinical trial: a multicentre, randomized, double-blind, placebocontrolled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis

A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin

Type I interferons have opposing effects during the emergence and recovery phases of colitis

Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation

IFN-lambda suppresses intestinal inflammation by non-translational regulation of neutrophil function

Critical role of interferons in gastrointestinal injury repair

Activation of Epithelial Signal Transducer and Activator of Transcription 1 by Interleukin 28 Controls Mucosal Healing in Mice With Colitis and Is Increased in Mucosa of Patients With Inflammatory Bowel Disease

Interferon Lambda Promotes Paneth Cell Death Via STAT1 Signaling in Mice and Is Increased in Inflamed Ileal Tissues of Patients With Crohn's Disease

Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion

Diverse intracellular pathogens activate type III interferon expression from peroxisomes

The unique regulation and functions of type III interferons in antiviral immunity

Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function

Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune Responses Elicited by Type I and Type III Interferons

Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

JAK2 rs10758669 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

Interferon-lambda: Immune Functions at Barrier Surfaces and Beyond

The international Genome sample resource (IGSR): A worldwide collection of genome variation incorporating the 1000 Genomes Project data

The ExAC browser: displaying reference data information from over 60 000 exomes

The IFN-lambda-IFN-lambdaR1-IL-10Rbeta Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity

The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family

Generating human intestinal tissue from pluripotent stem cells in vitro

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Genetic Manipulation of Human Intestinal Enteroids Demonstrates the Necessity of a Functional Fucosyltransferase 2 Gene for Secretor-Dependent Human Norovirus Infection

Disruption of Type III Interferon (IFN) Genes Ifnl2 and Ifnl3 Recapitulates Loss of the Type III IFN Receptor in the Mucosal Antiviral Response

Interferon lambda 4 expression is suppressed by the host during viral infection

Detection of allele specific differences in IFNL3 (IL28B) mRNA expression

The interferon landscape along the respiratory tract impacts the severity of COVID-19

A homeostatic interferon-lambda response to bacterial microbiota stimulates preemptive antiviral defense within discrete pockets of intestinal epithelium

Genetic and Structural Analysis of a SKIV2L Mutation Causing Trichohepato-enteric Syndrome

Fast and accurate short read alignment with Burrows-Wheeler transform

The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data

A comprehensive framework for prioritizing variants in exome sequencing studies of Mendelian diseases

Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number

Generation of Human Induced Pluripotent Stem Cells Using a Defined, Feeder-Free Reprogramming System

An in vivo model of human small intestine using pluripotent stem cells

Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium